NattoPharma ASA (OB:NATTO) made an offer to acquire the remaining 45.9% stake in Kaydence Pharma AS for NOK 12.7 million on February 15, 2021. Under the terms of consideration, NattoPharma ASA will acquire all the remaining shares of Kaydence currently not owned by NattoPharma at NOK 5 per share. NattoPharma currently owns a total of 3 million Shares in Kaydence Pharma, equivalent to 54.14% of Kaydence Pharma’s equity. Completion of the Kaydence Offer is subject to Compagnie Des Levures Lesaffre SA completing the NattoPharma Offer. Further, NattoPharma has received irrevocable commitments to accept the Kaydence Offer from shareholders which will bring NattoPharma's ownership to 80.9% of the Shares in Kaydence Pharma, including all shareholders represented at the Board of Directors and the top management of NattoPharma and Kaydence Pharma. The offer period is expected to commence on or prior to March 1, 2021 and continue for a period of 2 weeks. As of March 9, 2021, NattoPharma commenced the offer which will end on March 23, 2021, NattoPharma reserves the right to extend the Offer Period with up to 8 weeks that is until May 18, 2021. ABG Sundal Collier Holding ASA (OB:ABG) acted as financial advisor and Advokatfirmaet CLP acted as legal advisor to NattoPharma ASA. NattoPharma ASA (OB:NATTO) completed the acquisition of an additional 41.31% minority stake in Kaydence Pharma AS for NOK 11.4 million on March 23, 2021. Under the transaction, NattoPharma received valid acceptance in terms of 2.288587 million shares of Kaydence Pharma. Post completion, NattoPharma holds 95.45% stake representing 5.288587 million shares in Kaydence Pharma. Transaction completed post completion of Compagnie Des Levures Lesaffre SA' offer for NattoPharma, which was the condition to the transaction.